- Home
- PVL vs CGTX Comparison
PVL vs CGTX Comparison
Compare PVL & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVL
- CGTX
- Stock Information
- Founded
- PVL 2011
- CGTX 2007
- Country
- PVL United States
- CGTX United States
- Employees
- PVL N/A
- CGTX N/A
- Industry
- PVL Oil & Gas Production
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- PVL Energy
- CGTX Health Care
- Exchange
- PVL Nasdaq
- CGTX Nasdaq
- Market Cap
- PVL 60.4M
- CGTX 53.4M
- IPO Year
- PVL N/A
- CGTX 2021
- Fundamental
- Price
- PVL $1.82
- CGTX $1.54
- Analyst Decision
- PVL
- CGTX Strong Buy
- Analyst Count
- PVL 0
- CGTX 3
- Target Price
- PVL N/A
- CGTX $2.83
- AVG Volume (30 Days)
- PVL 49.9K
- CGTX 8.5M
- Earning Date
- PVL 01-01-0001
- CGTX 08-07-2025
- Dividend Yield
- PVL 4.56%
- CGTX N/A
- EPS Growth
- PVL N/A
- CGTX N/A
- EPS
- PVL 0.09
- CGTX N/A
- Revenue
- PVL $4,598,992.00
- CGTX N/A
- Revenue This Year
- PVL N/A
- CGTX N/A
- Revenue Next Year
- PVL N/A
- CGTX N/A
- P/E Ratio
- PVL $19.35
- CGTX N/A
- Revenue Growth
- PVL N/A
- CGTX N/A
- 52 Week Low
- PVL $1.30
- CGTX $0.22
- 52 Week High
- PVL $2.00
- CGTX $1.97
- Technical
- Relative Strength Index (RSI)
- PVL 50.68
- CGTX 77.80
- Support Level
- PVL $1.82
- CGTX $1.15
- Resistance Level
- PVL $1.90
- CGTX $0.74
- Average True Range (ATR)
- PVL 0.04
- CGTX 0.19
- MACD
- PVL 0.00
- CGTX 0.09
- Stochastic Oscillator
- PVL 46.67
- CGTX 69.59
About PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.